Does the media prefer NGNE or HRMY?

In the previous week, Harmony Biosciences had 12 more articles in the media than Neurogene. MarketBeat recorded 14 mentions for Harmony Biosciences and 2 mentions for Neurogene. Harmony Biosciences' average media sentiment score of 0.99 beat Neurogene's score of 0.58 indicating that Harmony Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Harmony Biosciences 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NGNE or IOVA?

In the previous week, Iovance Biotherapeutics had 6 more articles in the media than Neurogene. MarketBeat recorded 8 mentions for Iovance Biotherapeutics and 2 mentions for Neurogene. Neurogene's average media sentiment score of 0.58 beat Iovance Biotherapeutics' score of 0.22 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Iovance Biotherapeutics 1 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NGNE or RAPP more profitable?

Rapport Therapeutics' return on equity of -24.78% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Rapport Therapeutics N/A -24.78% -23.44%

Does the media favor NGNE or RAPP?

In the previous week, Rapport Therapeutics had 4 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Rapport Therapeutics and 2 mentions for Neurogene. Neurogene's average media sentiment score of 0.58 beat Rapport Therapeutics' score of 0.37 indicating that Neurogene is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Rapport Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is NGNE or SION more profitable?

Sionna Therapeutics' return on equity of -27.31% beat Neurogene's return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Sionna Therapeutics N/A -27.31% -25.88%

Does the media prefer NGNE or SION?

In the previous week, Sionna Therapeutics had 1 more articles in the media than Neurogene. MarketBeat recorded 3 mentions for Sionna Therapeutics and 2 mentions for Neurogene. Sionna Therapeutics' average media sentiment score of 1.22 beat Neurogene's score of 0.58 indicating that Sionna Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sionna Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is NGNE or PVLA more profitable?

Neurogene's return on equity of -37.88% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Neurogene N/A -37.88% -34.70% Palvella Therapeutics N/A -56.87% -42.50%

Does the media refer more to NGNE or PVLA?

In the previous week, Palvella Therapeutics had 9 more articles in the media than Neurogene. MarketBeat recorded 11 mentions for Palvella Therapeutics and 2 mentions for Neurogene. Palvella Therapeutics' average media sentiment score of 1.03 beat Neurogene's score of 0.58 indicating that Palvella Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Neurogene 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 4 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Neurogene (NGNE) Competitors

$33.64 +0.77 (+2.34%)

As of 12:36 PM Eastern

Compare

NGNE vs. HRMY, IOVA, RAPP, SION, and PVLA

Should you buy Neurogene stock or one of its competitors? MarketBeat compares Neurogene with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Neurogene include Harmony Biosciences (HRMY), Iovance Biotherapeutics (IOVA), Rapport Therapeutics (RAPP), Sionna Therapeutics (SION), and Palvella Therapeutics (PVLA).

How does Neurogene compare to Harmony Biosciences?

Neurogene (NASDAQ:NGNE) and Harmony Biosciences (NASDAQ:HRMY) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

52.4% of Neurogene shares are held by institutional investors. Comparatively, 86.2% of Harmony Biosciences shares are held by institutional investors. 11.7% of Neurogene shares are held by insiders. Comparatively, 11.0% of Harmony Biosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Neurogene currently has a consensus price target of $84.83, suggesting a potential upside of 149.47%. Harmony Biosciences has a consensus price target of $42.63, suggesting a potential upside of 10.97%. Given Neurogene's stronger consensus rating and higher probable upside, equities research analysts plainly believe Neurogene is more favorable than Harmony Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Harmony Biosciences	1 Sell rating(s)	4 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.50

Harmony Biosciences has higher revenue and earnings than Neurogene. Neurogene is trading at a lower price-to-earnings ratio than Harmony Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	577.74	-$90.35M	-$4.55	N/A
Harmony Biosciences	$868.45M	2.56	$158.69M	$2.48	15.49

Harmony Biosciences has a net margin of 16.20% compared to Neurogene's net margin of 0.00%. Harmony Biosciences' return on equity of 17.19% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Harmony Biosciences	16.20%	17.19%	11.99%

Neurogene has a beta of 1.7, meaning that its share price is 70% more volatile than the broader market. Comparatively, Harmony Biosciences has a beta of 0.96, meaning that its share price is 4% less volatile than the broader market.

In the previous week, Harmony Biosciences had 12 more articles in the media than Neurogene. MarketBeat recorded 14 mentions for Harmony Biosciences and 2 mentions for Neurogene. Harmony Biosciences' average media sentiment score of 0.99 beat Neurogene's score of 0.58 indicating that Harmony Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Harmony Biosciences	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Harmony Biosciences beats Neurogene on 11 of the 17 factors compared between the two stocks.

How does Neurogene compare to Iovance Biotherapeutics?

Neurogene (NASDAQ:NGNE) and Iovance Biotherapeutics (NASDAQ:IOVA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability.

Neurogene currently has a consensus price target of $84.83, suggesting a potential upside of 149.47%. Iovance Biotherapeutics has a consensus price target of $8.43, suggesting a potential upside of 92.21%. Given Neurogene's stronger consensus rating and higher possible upside, research analysts plainly believe Neurogene is more favorable than Iovance Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Iovance Biotherapeutics	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.30

Neurogene has higher earnings, but lower revenue than Iovance Biotherapeutics. Neurogene is trading at a lower price-to-earnings ratio than Iovance Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	577.74	-$90.35M	-$4.55	N/A
Iovance Biotherapeutics	$263.50M	7.43	-$390.98M	-$0.95	N/A

In the previous week, Iovance Biotherapeutics had 6 more articles in the media than Neurogene. MarketBeat recorded 8 mentions for Iovance Biotherapeutics and 2 mentions for Neurogene. Neurogene's average media sentiment score of 0.58 beat Iovance Biotherapeutics' score of 0.22 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Iovance Biotherapeutics	1 Very Positive mention(s)	0 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

52.4% of Neurogene shares are held by institutional investors. Comparatively, 77.0% of Iovance Biotherapeutics shares are held by institutional investors. 11.7% of Neurogene shares are held by company insiders. Comparatively, 7.8% of Iovance Biotherapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Neurogene has a net margin of 0.00% compared to Iovance Biotherapeutics' net margin of -123.92%. Neurogene's return on equity of -37.88% beat Iovance Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Iovance Biotherapeutics	-123.92%	-50.17%	-38.77%

Neurogene has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, Iovance Biotherapeutics has a beta of 0.71, indicating that its share price is 29% less volatile than the broader market.

Summary

Neurogene beats Iovance Biotherapeutics on 11 of the 17 factors compared between the two stocks.

How does Neurogene compare to Rapport Therapeutics?

Neurogene (NASDAQ:NGNE) and Rapport Therapeutics (NASDAQ:RAPP) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, risk, media sentiment and valuation.

Rapport Therapeutics' return on equity of -24.78% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Rapport Therapeutics	N/A	-24.78%	-23.44%

52.4% of Neurogene shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 12.5% of Rapport Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Neurogene has higher revenue and earnings than Rapport Therapeutics. Rapport Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	577.74	-$90.35M	-$4.55	N/A
Rapport Therapeutics	N/A	N/A	-$111.48M	-$2.60	N/A

In the previous week, Rapport Therapeutics had 4 more articles in the media than Neurogene. MarketBeat recorded 6 mentions for Rapport Therapeutics and 2 mentions for Neurogene. Neurogene's average media sentiment score of 0.58 beat Rapport Therapeutics' score of 0.37 indicating that Neurogene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Rapport Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Neurogene currently has a consensus price target of $84.83, indicating a potential upside of 149.47%. Rapport Therapeutics has a consensus price target of $57.86, indicating a potential upside of 39.79%. Given Neurogene's stronger consensus rating and higher possible upside, equities research analysts plainly believe Neurogene is more favorable than Rapport Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Rapport Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Neurogene has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, Rapport Therapeutics has a beta of 0.97, suggesting that its stock price is 3% less volatile than the broader market.

Summary

Neurogene beats Rapport Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Neurogene compare to Sionna Therapeutics?

Neurogene (NASDAQ:NGNE) and Sionna Therapeutics (NASDAQ:SION) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, valuation, analyst recommendations, institutional ownership, media sentiment, earnings, profitability and dividends.

52.4% of Neurogene shares are held by institutional investors. 11.7% of Neurogene shares are held by insiders. Comparatively, 5.1% of Sionna Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Sionna Therapeutics had 1 more articles in the media than Neurogene. MarketBeat recorded 3 mentions for Sionna Therapeutics and 2 mentions for Neurogene. Sionna Therapeutics' average media sentiment score of 1.22 beat Neurogene's score of 0.58 indicating that Sionna Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sionna Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Neurogene has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, Sionna Therapeutics has a beta of 1.32, suggesting that its stock price is 32% more volatile than the broader market.

Sionna Therapeutics' return on equity of -27.31% beat Neurogene's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Sionna Therapeutics	N/A	-27.31%	-25.88%

Sionna Therapeutics has lower revenue, but higher earnings than Neurogene. Sionna Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	577.74	-$90.35M	-$4.55	N/A
Sionna Therapeutics	N/A	N/A	-$75.27M	-$1.93	N/A

Neurogene currently has a consensus price target of $84.83, suggesting a potential upside of 149.47%. Sionna Therapeutics has a consensus price target of $53.22, suggesting a potential upside of 5.07%. Given Neurogene's stronger consensus rating and higher possible upside, analysts clearly believe Neurogene is more favorable than Sionna Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Sionna Therapeutics	2 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	3 Strong Buy rating(s)	2.85

Summary

Sionna Therapeutics beats Neurogene on 8 of the 15 factors compared between the two stocks.

How does Neurogene compare to Palvella Therapeutics?

Neurogene (NASDAQ:NGNE) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, dividends, valuation, risk, profitability, earnings and analyst recommendations.

Neurogene has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

52.4% of Neurogene shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 11.7% of Neurogene shares are owned by company insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Palvella Therapeutics has higher revenue and earnings than Neurogene. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Neurogene, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurogene	$930K	577.74	-$90.35M	-$4.55	N/A
Palvella Therapeutics	$42.81M	49.50	-$41.72M	-$4.17	N/A

Neurogene presently has a consensus price target of $84.83, suggesting a potential upside of 149.47%. Palvella Therapeutics has a consensus price target of $207.36, suggesting a potential upside of 40.31%. Given Neurogene's higher probable upside, equities research analysts plainly believe Neurogene is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurogene	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	2 Strong Buy rating(s)	3.00
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	12 Buy rating(s)	2 Strong Buy rating(s)	3.00

Neurogene's return on equity of -37.88% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurogene	N/A	-37.88%	-34.70%
Palvella Therapeutics	N/A	-56.87%	-42.50%

In the previous week, Palvella Therapeutics had 9 more articles in the media than Neurogene. MarketBeat recorded 11 mentions for Palvella Therapeutics and 2 mentions for Neurogene. Palvella Therapeutics' average media sentiment score of 1.03 beat Neurogene's score of 0.58 indicating that Palvella Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurogene	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Neurogene and Palvella Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

Get Neurogene News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NGNE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NGNE vs. The Competition

Export

Metric	Neurogene	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$538.32M	$3.53B	$6.80B	$12.89B
Dividend Yield	N/A	3.79%	2.60%	10.03%
P/E Ratio	-7.49	7.33	279.90	25.40
Price / Sales	577.74	1,274.10	648.58	114.39
Price / Cash	N/A	44.80	28.64	34.82
Price / Book	1.99	17.12	11.10	6.30
Net Income	-$90.35M	-$12.52M	$3.48B	$347.60M
7 Day Performance	2.42%	1.54%	1.93%	2.53%
1 Month Performance	-3.72%	-6.32%	-3.29%	-2.57%
1 Year Performance	56.65%	49.25%	62.38%	20.26%

Neurogene Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NGNE Neurogene	3.1548 of 5 stars	$33.64 +2.3%	$84.83 +152.2%	+50.9%	$531.51M	$930K	N/A	90	News Coverage Positive News Upcoming Earnings
HRMY Harmony Biosciences	4.0473 of 5 stars	$36.29 +0.8%	$42.50 +17.1%	+3.5%	$2.11B	$899.11M	14.73	200	News Coverage Earnings Report Gap Up
IOVA Iovance Biotherapeutics	2.6213 of 5 stars	$4.71 -3.9%	$8.43 +78.9%	+61.2%	$2.11B	$263.50M	N/A	500	Upcoming Earnings
RAPP Rapport Therapeutics	2.8394 of 5 stars	$42.51 +0.9%	$57.86 +36.1%	+188.3%	$2.05B	$20M	N/A	N/A	Upcoming Earnings
SION Sionna Therapeutics	1.7019 of 5 stars	$44.52 -1.9%	$53.22 +19.6%	+191.1%	$2.03B	N/A	N/A	35	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NGNE) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Neurogene (NGNE) Competitors

NGNE vs. HRMY, IOVA, RAPP, SION, and PVLA

How does Neurogene compare to Harmony Biosciences?

Summary

How does Neurogene compare to Iovance Biotherapeutics?

Summary

How does Neurogene compare to Rapport Therapeutics?

Summary

How does Neurogene compare to Sionna Therapeutics?

Summary

How does Neurogene compare to Palvella Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Neurogene (NGNE) Competitors

NGNE vs. HRMY, IOVA, RAPP, SION, and PVLA

How does Neurogene compare to Harmony Biosciences?

Do insiders & institutionals have more ownership in NGNE or HRMY?

Do analysts rate NGNE or HRMY?

Which has better earnings & valuation, NGNE or HRMY?

Is NGNE or HRMY more profitable?

Which has more volatility & risk, NGNE or HRMY?

Does the media prefer NGNE or HRMY?

Summary

How does Neurogene compare to Iovance Biotherapeutics?

Do analysts rate NGNE or IOVA?

Which has better earnings & valuation, NGNE or IOVA?

Does the media refer more to NGNE or IOVA?

Do insiders & institutionals believe in NGNE or IOVA?

Is NGNE or IOVA more profitable?

Which has more volatility and risk, NGNE or IOVA?

Summary

How does Neurogene compare to Rapport Therapeutics?

Is NGNE or RAPP more profitable?

Do institutionals & insiders believe in NGNE or RAPP?

Which has higher valuation and earnings, NGNE or RAPP?

Does the media favor NGNE or RAPP?

Do analysts rate NGNE or RAPP?

Which has more volatility and risk, NGNE or RAPP?

Summary

How does Neurogene compare to Sionna Therapeutics?

Do insiders and institutionals hold more shares of NGNE or SION?

Does the media prefer NGNE or SION?

Which has more risk and volatility, NGNE or SION?

Is NGNE or SION more profitable?

Which has preferable valuation and earnings, NGNE or SION?

Do analysts recommend NGNE or SION?

Summary

How does Neurogene compare to Palvella Therapeutics?

Which has more volatility & risk, NGNE or PVLA?

Do insiders & institutionals hold more shares of NGNE or PVLA?

Which has higher valuation and earnings, NGNE or PVLA?

Do analysts rate NGNE or PVLA?

Is NGNE or PVLA more profitable?

Does the media refer more to NGNE or PVLA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NGNE vs. The Competition

Neurogene Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools